Wall Street has set ambitious price targets for the stocks in this article. While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional pressures that can sometimes lead to overly optimistic forecasts.
At StockStory, we look beyond the headlines with our independent analysis to determine whether these bullish calls are justified. Keeping that in mind, here is one stock where Wall Street’s positive outlook is supported by strong fundamentals and two where analysts may be overlooking some important risks.
Two Stocks to Sell:
MSCI (MSCI)
Consensus Price Target: $678.31 (28.3% implied return)
Originally known as Morgan Stanley Capital International before becoming independent in 2007, MSCI (NYSE: MSCI) provides critical decision support tools, indexes, and analytics that help global investors understand risk and return factors and build more effective investment portfolios.
Why Do We Think Twice About MSCI?
- Negative return on equity shows that some of its growth strategies have backfired
MSCI is trading at $528.54 per share, or 27.7x forward P/E. If you’re considering MSCI for your portfolio, see our FREE research report to learn more.
Franklin BSP Realty Trust (FBRT)
Consensus Price Target: $13.25 (55.2% implied return)
Operating as a specialized real estate investment trust (REIT) with roots dating back to 2012, Franklin BSP Realty Trust (NYSE: FBRT) originates and manages a diversified portfolio of commercial real estate debt investments secured by properties in the United States and abroad.
Why Do We Think FBRT Will Underperform?
- 6.1% annual net interest income growth over the last five years was slower than its banking peers
- Net interest income is projected to tank by 5.7% over the next 12 months as demand evaporates
- Falling earnings per share over the last three years has some investors worried as stock prices ultimately follow EPS over the long term
Franklin BSP Realty Trust’s stock price of $8.54 implies a valuation ratio of 0.6x forward P/B. To fully understand why you should be careful with FBRT, check out our full research report (it’s free).
One Stock to Watch:
BioMarin Pharmaceutical (BMRN)
Consensus Price Target: $88.87 (62.7% implied return)
Pioneering treatments for conditions that often had no previous therapeutic options, BioMarin Pharmaceutical (NASDAQ: BMRN) develops and commercializes therapies that address the root causes of rare genetic disorders, particularly those affecting children.
Why Could BMRN Be a Winner?
- 15.4% annual revenue growth over the last two years surpassed the sector average as its offerings resonated with customers
- Incremental sales over the last five years have been highly profitable as its earnings per share increased by 13.8% annually, topping its revenue gains
- Free cash flow margin expanded by 17.2 percentage points over the last five years, providing additional flexibility for investments and share buybacks/dividends
At $54.63 per share, BioMarin Pharmaceutical trades at 10.3x forward P/E. Is now a good time to buy? See for yourself in our comprehensive research report, it’s free.
High-Quality Stocks for All Market Conditions
ONE MORE THING: Top 5 Growth Stocks. The biggest stock winners almost always had one thing in common before they ran. Revenue growing like crazy. Meta. CrowdStrike. Broadcom. Our AI flagged all three. They returned 315%, 314%, and 455%, respectively.
Find out which 5 stocks it's flagging for this month — FREE. Get Our Top 5 Growth Stocks for Free HERE.
Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today.
